“TESTSEA independently developed products COVID-19 diagnostic test kits continued to expand market and its sales revenue surpassed 1.2 billion yuan($ 178 million) in the first quarter of this year, , which is a year-on-year increase of 600%.” During his interview with Hangzhou Yuhang broadcaster, the director of Testsea Zhou Bin says.
Since the outbreak of COVID-19, Testsea has developed 2019-nCoV test kits, and has followed up the R & D of several differential diagnostic reagents for mutant strains, which were sold to more than 100 countries and regions through international distributors and government procurement.
“In response to the increasing severe pandemic, Testsea have expanded production base, added the equipment and personnel. Testsea also made full use of its own expertise and advantages, adhered to the policy of high-quality development. With the ramping up of production capacity, we achieved rapid growth in business performance since 2020.” Said Zhou Bin.
With a heart of gratitude, we will work harder and lead Testsea to strive to overcome all kinds of difficulties and solve all kinds of problems, so as to carry a greater social responsibility and continue to contribute to the global epidemic prevention and control and make full preparations for the post-COVID-19 era.
Meanwhile, the demand of our regular rapid diagnosis products are going up, our goal for the whole year is expected to achieve 2.0 billion yuan($ 300 million) by 2022.
Our enterprise became bigger and bigger, with more and more standardized internal governance, more and more leading talents and professional talents, the company took a solid step in global layout.
Testsea always dedicates itself to developing more accurate and efficient solutions in identifying pathogens, diagnosing diseases and guarding health.
Post time: May-19-2022